Skip to main content
. Author manuscript; available in PMC: 2019 Jun 26.
Published in final edited form as: Biomaterials. 2019 Mar 14;205:94–105. doi: 10.1016/j.biomaterials.2019.03.011

Figure 5. cGAMP MPs anti-tumor efficacy is STING dependent.

Figure 5.

(A-B) C57BL6/J mice or B6(Cg)-Tmem173tm1.2Camb/J (Tmem173−/−) were inoculated with B16F10 tumors on day 0. Starting on day 6, 9, and 12 mice were treated with either PBS or 10 μg cGAMP encapsulated in Ace-DEX MPs by i.t. administration. Tumor volume was monitored every 3 days and mice were sacrificed when tumors reached 20 mm in diameter (n = 8–10 mice ± mean SEM over 2 experiments). A. Two-way ANOVA, B. Mantel Cox test (B) ***p < 0.001, ****p < 0.0001